Heparin 5000 IU/ml 5 ml, 5 pcs.

The mechanism of action of sodium heparin is based primarily on its binding to antithrombin III, which is a natural inhibitor of activated clotting factors – IIa (thrombin), IXa, Ha, XIa and XIIa. Sodium heparin binds to antithrombin III and causes conformational changes in its molecule.

Indications

prevention and treatment of venous thrombosis (including thrombosis of the superficial and deep veins of the lower extremities, renal vein thrombosis) and pulmonary embolism;
prevention and treatment of thromboembolic complications associated with atrial fibrillation;
prevention and treatment of peripheral arterial embolisms (including those associated with mitral heart defects);
treatment of acute and chronic consumption coagulopathies (including stage I of DIC syndrome);
acute coronary syndrome without persistent ST segment elevation on the ECG (unstable angina, myocardial infarction without ST segment elevation on the ECG);
myocardial infarction with ST segment elevation: with thrombolytic therapy, with primary percutaneous coronary revascularization (balloon angioplasty with or without stenting) and with a high risk of arterial or venous thrombosis and thromboembolism;
prevention and treatment of microthrombosis and microcirculation disorders, incl. with hemolytic uremic syndrome, glomerulonephritis (including lupus nephritis) and with forced diuresis;
prevention of blood clotting during blood transfusion, in extracorporeal circulation systems (extracorporeal circulation during heart surgery, hemosorption, cytapheresis) and during hemodialysis;
processing of peripheral venous catheters.

Pharmacological effect

The mechanism of action of sodium heparin is based primarily on its binding to antithrombin III, which is a natural inhibitor of activated blood coagulation factors – IIa (thrombin), IXa, Xa, XIa and XIIa. Sodium heparin binds to antithrombin III and causes conformational changes in its molecule.

Special instructions

Treatment with large doses is recommended in a hospital setting. Platelet counts should be monitored before starting treatment, on the first day of treatment and at short intervals throughout the entire period of administration of sodium heparin, especially between 6 and 14 days after the start of treatment.

Active ingredient

Heparin sodium

Composition

Active ingredient:

heparin sodium

Pregnancy

Heparin sodium does not penetrate the placental barrier. To date, there is no data indicating the possibility of fetal malformations due to the use of sodium heparin during pregnancy: there are also no results of animal experiments that would indicate the embryo- or fetotoxic effect of sodium heparin. However, there is evidence of an increased risk of premature birth and spontaneous abortion associated with bleeding.

Contraindications

Hypersensitivity;

bleeding diathesis, hemophilia, vasculitis, thrombocytopenia (including a history of heparin-induced), bleeding, leukemia, increased vascular permeability, polyps, malignant neoplasms and ulcerative lesions of the gastrointestinal tract, esophageal varices, severe uncontrolled arterial hypertension, acute bacterial endocarditis, trauma (especially traumatic brain injury), recent surgical intervention on the eyes, brain and spine, severe liver and/or kidney dysfunction.

Side Effects

From the nervous system and sensory organs: dizziness, headache.

From the cardiovascular system and blood (hematopoiesis, hemostasis): thrombocytopenia (6% of patients) – early (2–4 days of treatment) and late (autoimmune), in rare cases with a fatal outcome; hemorrhagic complications – bleeding from the gastrointestinal tract or urinary tract, retroperitoneal hemorrhages in the ovaries, adrenal glands (with the development of acute adrenal insufficiency).

From the gastrointestinal tract: loss of appetite, nausea, vomiting, diarrhea, increased levels of transaminases in the blood.

Allergic reactions: skin flushing, drug fever, urticaria, rash, itching, bronchospasm, anaphylactoid reactions, anaphylactic shock.

Other: with long-term use – alopecia, osteoporosis, soft tissue calcification, inhibition of aldosterone synthesis; injection reactions – irritation, hematoma, pain during injection.

Interaction

Pharmaceutical interactions: sodium heparin solution is compatible only with 0.9% sodium chloride solution.

Overdose

Symptoms: signs of bleeding.

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 25 °C.

Shelf life

2 years

Manufacturer

Slavic Pharmacy, Russia